Vasopressors for the Treatment of Septic Shock: Systematic Review and Meta-Analysis.

<h4>Objective</h4>International guidelines recommend dopamine or norepinephrine as first-line vasopressor agents in septic shock. Phenylephrine, epinephrine, vasopressin and terlipressin are considered second-line agents. Our objective was to assess the evidence for the efficiency and sa...

Full description

Bibliographic Details
Main Authors: Tomer Avni, Adi Lador, Shaul Lev, Leonard Leibovici, Mical Paul, Alon Grossman
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0129305
id doaj-5adcdc3bf1e94ed2883769a6d370158a
record_format Article
spelling doaj-5adcdc3bf1e94ed2883769a6d370158a2021-03-04T07:43:23ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01108e012930510.1371/journal.pone.0129305Vasopressors for the Treatment of Septic Shock: Systematic Review and Meta-Analysis.Tomer AvniAdi LadorShaul LevLeonard LeiboviciMical PaulAlon Grossman<h4>Objective</h4>International guidelines recommend dopamine or norepinephrine as first-line vasopressor agents in septic shock. Phenylephrine, epinephrine, vasopressin and terlipressin are considered second-line agents. Our objective was to assess the evidence for the efficiency and safety of all vasopressors in septic shock.<h4>Methods</h4>Systematic review and meta-analysis. We searched electronic database of MEDLINE, CENTRAL, LILACS and conference proceedings up to June 2014. We included randomized controlled trials comparing different vasopressors for the treatment of adult patients with septic shock. Primary outcome was all-cause mortality. Other clinical and hemodynamic measurements were extracted as secondary outcomes. Risk ratios (RR) and mean differences with 95% confidence intervals (CI) were pooled.<h4>Results</h4>Thirty-two trials (3,544 patients) were included. Compared to dopamine (866 patients, 450 events), norepinephrine (832 patients, 376 events) was associated with decreased all-cause mortality, RR 0.89 (95% CI 0.81-0.98), corresponding to an absolute risk reduction of 11% and number needed to treat of 9. Norepinephrine was associated with lower risk for major adverse events and cardiac arrhythmias compared to dopamine. No other mortality benefit was demonstrated for the comparisons of norepinephrine to epinephrine, phenylephrine and vasopressin / terlipressin. Hemodynamic data were similar between the different vasopressors, with some advantage for norepinephrine in central venous pressure, urinary output and blood lactate levels.<h4>Conclusions</h4>Evidence suggests a survival benefit, better hemodynamic profile and reduced adverse events rate for norepinephrine over dopamine. Norepinephrine should be regarded as the first line vasopressor in the treatment of septic shock.https://doi.org/10.1371/journal.pone.0129305
collection DOAJ
language English
format Article
sources DOAJ
author Tomer Avni
Adi Lador
Shaul Lev
Leonard Leibovici
Mical Paul
Alon Grossman
spellingShingle Tomer Avni
Adi Lador
Shaul Lev
Leonard Leibovici
Mical Paul
Alon Grossman
Vasopressors for the Treatment of Septic Shock: Systematic Review and Meta-Analysis.
PLoS ONE
author_facet Tomer Avni
Adi Lador
Shaul Lev
Leonard Leibovici
Mical Paul
Alon Grossman
author_sort Tomer Avni
title Vasopressors for the Treatment of Septic Shock: Systematic Review and Meta-Analysis.
title_short Vasopressors for the Treatment of Septic Shock: Systematic Review and Meta-Analysis.
title_full Vasopressors for the Treatment of Septic Shock: Systematic Review and Meta-Analysis.
title_fullStr Vasopressors for the Treatment of Septic Shock: Systematic Review and Meta-Analysis.
title_full_unstemmed Vasopressors for the Treatment of Septic Shock: Systematic Review and Meta-Analysis.
title_sort vasopressors for the treatment of septic shock: systematic review and meta-analysis.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2015-01-01
description <h4>Objective</h4>International guidelines recommend dopamine or norepinephrine as first-line vasopressor agents in septic shock. Phenylephrine, epinephrine, vasopressin and terlipressin are considered second-line agents. Our objective was to assess the evidence for the efficiency and safety of all vasopressors in septic shock.<h4>Methods</h4>Systematic review and meta-analysis. We searched electronic database of MEDLINE, CENTRAL, LILACS and conference proceedings up to June 2014. We included randomized controlled trials comparing different vasopressors for the treatment of adult patients with septic shock. Primary outcome was all-cause mortality. Other clinical and hemodynamic measurements were extracted as secondary outcomes. Risk ratios (RR) and mean differences with 95% confidence intervals (CI) were pooled.<h4>Results</h4>Thirty-two trials (3,544 patients) were included. Compared to dopamine (866 patients, 450 events), norepinephrine (832 patients, 376 events) was associated with decreased all-cause mortality, RR 0.89 (95% CI 0.81-0.98), corresponding to an absolute risk reduction of 11% and number needed to treat of 9. Norepinephrine was associated with lower risk for major adverse events and cardiac arrhythmias compared to dopamine. No other mortality benefit was demonstrated for the comparisons of norepinephrine to epinephrine, phenylephrine and vasopressin / terlipressin. Hemodynamic data were similar between the different vasopressors, with some advantage for norepinephrine in central venous pressure, urinary output and blood lactate levels.<h4>Conclusions</h4>Evidence suggests a survival benefit, better hemodynamic profile and reduced adverse events rate for norepinephrine over dopamine. Norepinephrine should be regarded as the first line vasopressor in the treatment of septic shock.
url https://doi.org/10.1371/journal.pone.0129305
work_keys_str_mv AT tomeravni vasopressorsforthetreatmentofsepticshocksystematicreviewandmetaanalysis
AT adilador vasopressorsforthetreatmentofsepticshocksystematicreviewandmetaanalysis
AT shaullev vasopressorsforthetreatmentofsepticshocksystematicreviewandmetaanalysis
AT leonardleibovici vasopressorsforthetreatmentofsepticshocksystematicreviewandmetaanalysis
AT micalpaul vasopressorsforthetreatmentofsepticshocksystematicreviewandmetaanalysis
AT alongrossman vasopressorsforthetreatmentofsepticshocksystematicreviewandmetaanalysis
_version_ 1714808148317962240